2019;140:e596 646. 4. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137 61. 5. Elder DHJ, Wei L, Szwejkowski BR, et al. The impact of renin-angiotensin- aldosterone system blockade on heart failure outcomes and mortality in patients identified to have aortic regurgitation: a large population cohort study. J Am Coll Cardiol. 2011;58:2084 91. 6. Fioretti P, Benussi B, Scardi S, et al. Afterload reduction with nifedipine in aortic insufficiency. Am J Cardiol. 1982;49:1728 32. 7. Lin M, Chiang HT, Lin SL, et al. Vasodilator therapy in chronic asymptom- atic aortic regurgitation: enalapril versus hydralazine therapy. J Am Coll Cardiol. 1994;24:1046 53. 8. S ndergaard L, Aldershvile J, Hildebrandt P, et al. Vasodilatation with felodipine in chronic asymptomatic aortic regurgitation. Am Heart J. 2000;139:667 74. 9. Sampat U, Varadarajan P, Turk R, et al. Effect of beta-blocker therapy on survival in patients with severe aortic regurgitation results from a cohort of 756 patients. J Am Coll Cardiol. 2009;54:452 7. 4.3.3. Timing of Intervention 1. Bonow RO, Borer JS, Rosing DR, et al. Preoperative exercise capacity in symptomatic patients with aortic regurgitation as a predictor of post- operative left ventricular function and long-term prognosis. Circulation. 1980;62:1280 90. 2. Klodas E, Enriquez-Sarano M, Tajik AJ, et al. Optimizing timing of surgical correction in patients with severe aortic regurgitation: role of symptoms. J Am Coll Cardiol. 1997;30:746 52. 3. Chaliki HP, Mohty D, Avierinos J-F, et al. Outcomes after aortic valve re- placement in patients with severe aortic regurgitation and markedly re- duced left ventricular function. Circulation. 2002;106:2687 93. 4. 